OSLM
Outcome Studies
in Laboratory Medicine
guest
👤
Learn more about this platform
c
Categories
p
Projects
Highlighted
Trial protocol
Study Design
RCT
Cluster RCT
Observational
Model
Meta-analysis
Review
Guideline
Outcomes
Change patient management
Clinical outcomes
Economics
Operational efficiencies
Patient-centeredness
Safety
Guide Policy Making
Other
Uncategorized
Antibiotic Guidance
ACT Guided Heparinization
Cancer
COVID-19
Cardiovascular Disease
Diabetes
HIV POCT
Inflammatory Bowel Disease
Liver Disease
Kidney Disease
Newborn Screening
MALDI-TOF MS For Microorganism Identification
Preeclampsia
Therapeutic drug monitoring
Pharmacogenetic and Pharmacogenomics
Viscoelastic Testing
Please contact us for any suggestions
Zhen Zhao
Smeralda Skenderaj
Search
Search
Categories:
Model
118 Publications
found
The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
b
The Milbank quarterly
June 1, 2016
p
Newborn Screening
c
Economics
Model
Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
b
The Journal of pediatrics
May 1, 2016
p
Newborn Screening
c
Economics
Model
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
b
PloS one
January 1, 2016
p
Cancer
c
Economics
Model
Cost-Effectiveness of the ‘One4All’ HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.
b
PloS one
January 1, 2016
p
HIV POCT
c
Economics
Model
Impact and Cost-Effectiveness of Point-Of-Care CD4 Testing on the HIV Epidemic in South Africa.
b
PloS one
January 1, 2016
p
HIV POCT
c
Economics
Model
A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola.
b
The Journal of pediatrics
December 1, 2015
p
Newborn Screening
c
Economics
Model
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
b
Lung cancer (Amsterdam, Netherlands)
October 1, 2015
p
Cancer
c
Economics
Model
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
b
Clinical lung cancer
September 1, 2015
p
Cancer
c
Economics
Model
Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries.
b
The Journal of infectious diseases
August 15, 2015
p
HIV POCT
c
Economics
Model
Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency.
b
Pediatrics
August 1, 2015
p
Newborn Screening
c
Economics
Model
Previous Page
1
…
8
9
10
11
12
Next Page
